This study represents, to our knowledge, the first investigation aimed at evaluating the prognostic significance of CD133 in a series of patients with gliomas in which both tumor CD133 expression and promoter methylation status were simultaneously evaluated. The gene discussed is PROM1; the disease is central nervous system cancer.